- Development of Animal-free Peptones for Mammalian and Microbial CulturePosted 5 days ago
- Cool Tool – Fluid Transfer Sets Specifically Designed for Sterile Transfer of Cell Therapy Based ProductsPosted 6 days ago
- Electroporation-based Transfection Demonstrates Consistent Antibody Quality and Glycosylation Patterns for Biotherapeutic Product DevelopmentPosted 1 month ago
- Cool Tool – Cell Culture Basics Virtual LabPosted 1 month ago
- Video – Bioprocessing pH Probe Selection and MaintenancePosted 1 month ago
- Cool Tool – Kits to Simplify and Standardize Your Immune Cell CulturesPosted 1 month ago
- Cool Tool – An Optimized, Chemically-Defined, Animal Component-Free Neural Basal MediumPosted 1 month ago
- Cool Tool – Lynx CDR Connectors to Improve Sterile Fluid Transfer in BiomanufacturingPosted 1 month ago
- Improving Glycosylation Patterns and Consistency Through Media OptimizationPosted 1 month ago
- Cool Tool – Online Cell Culture Media Formulation ToolPosted 2 months ago
Protein Reprogrammed iPS Stem Cells Show Progress in an Animal-Disease Model for Parkinson Disease
The reprogramming of fibroblasts into iPS stem cells via modified proteins was first reported in a landmark publication in Cell Stem Cell in 2009. The new technique, which involved only four genetically engineered proteins, had the potential to lead to the first clinic-ready human induced pluripotent stem (iPS) cells. The majority of human iPSC (hiPSC) lines to date had been generated using lentiviral and retroviral methods, which are known to generate multiple chromosomal integrations and possible genetic dysfunction. This new protein-based method eliminates the potential risks associated with the use of viruses, DNA transfection, and potentially harmful chemicals. Using the new method, protein-based reprogrammed iPS cells were able to be maintained for more than 35 passages and were successfully differentiated into derivatives of all three embryonic germ layers both in vitro and in teratomas.
Until recently, there had been no studies that systematically compared the physiological and differentiation properties of hiPSCs generated using different reprogramming methods in the treatment of disease. A new study headed by Sang-Hun Lee and Kwang-Soo Kim has now compared the ability of neural precursor cells (NPCs) derived from either protein-based iPS cells or viral-based iPS cells to reverse disease in a rat model of Parkinson disease. Lee found several problems with nerve cells derived from virus-based iPS cells that precluded their use in the Parkinson disease model. However, nerve cells derived from protein-based human iPS cells rescued motor defects when transplanted into the brain of rats modeling Parkinson disease. Their conclusion is that protein-based human iPS cells could support the clinical potential of personalized cell therapy.
Specifically they found that NPCs derived by lentivirus-based hiPSCs exhibited residual expression of exogenous reprogramming genes. However, cells derived from retrovirus- and protein-based hiPSCs did not. Furthermore, NPCs derived from virus-based hiPSCs exhibited early senescence and apoptotic cell death during passaging. In contrast, NPCs derived from hESCs and protein-based hiPSCs were highly expandable without senescence.